OTC · Biotechnology

Kuros Biosciences AG (CSBTF) Stock

$25.57 +0.00% OTC: CSBTF Healthcare

Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio.

Valuation

MetricValue
Price$25.57
Market Cap$1.01B
P/E Ratio478.87
P/B Ratio11.93
P/S Ratio6.21
EPS (TTM)$0.05
52-Week High$42.81
52-Week Low$22.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2.28%
ROA1.53%
ROCE10.51%
Gross Margin87.02%
Operating Margin5.99%
Net Margin1.26%
Debt/Equity0.06
Current Ratio1.96

Annual Financials (USD)

Metric20212022202320242025
Revenue$14.0M$18.0M$34.0M$76.0M$121.0M
Operating Profit$-9.0M$-13.0M$-13.0M$-5.0M$7.0M
Net Profit$-8.0M$-15.0M$-14.0M$-4.0M$2.0M
EPS$-0.23$-0.43$-0.38$-0.10$0.05
Op Margin-63.5%-74.8%-39.3%-6.6%6.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$91.0M$83.0M$71.0M$85.0M$107.0M
Total Liabilities$14.0M$14.0M$15.0M$26.0M$49.0M
Cash$29.0M$24.0M$14.0M$17.0M$16.0M
Borrowings$2.0M$2.0M$2.0M$2.0M$1.0M

Latest News

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich GlobeNewswire · Jun 17, 2026 European Growth Stocks With High Insider Ownership Simply Wall St. · Jun 12, 2026 European Growth Companies With High Insider Ownership June 2026 Simply Wall St. · Jun 11, 2026 High Growth European Companies With Insider Ownership In June 2026 Simply Wall St. · Jun 10, 2026 3 European Growth Stocks Insiders Are Eager To Hold Simply Wall St. · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-7.0M$-9.0M$3.0M$0
Investing Cash Flow$-1.0M$-1.0M$-1.0M$-2.0M$-4.0M
Financing Cash Flow$6.0M$-2.0M$-1.0M$-1.0M$-1.0M
Net Cash Flow$0$-5.0M$-10.0M$4.0M$0
Free Cash Flow$-6.0M$-8.0M$-9.0M$2.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio9.37
EV / EBITDA77.76
FCF Yield-0.35%
Quick Ratio1.45
Interest Coverage1.19
Return 1Y-28.54%
Return 3Y1252.89%
Return 5Y—

Ownership

Insiders Held28.90%
Institutions Held22.31%
Institutions Float Held31.38%
Institutional HolderSharesReport Date
iShares Trust-iShares Core MSCI EAFE ETF217,1542026-06-30
iShares Trust-iShares MSCI EAFE Small-Cap ETF107,7462026-06-30
JNL Series Trust-JNL Multi-Manager International Small Cap Fund90,4362026-03-31
INVESTMENT MANAGERS SERIES TRT-WCM Intl Small Cap Growth Fd.87,6182026-03-31
American Century World Mutual Fd.s, Inc.-Intl OPPORTUNITIES Fd.82,8802026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASCLFAscletis Pharma Inc. $1.42 +0.00% -20.87 $1.49B 0.00%
CHIZFChina Traditional Chinese Medicine Holdings Co. Limited $0.16 +0.00% -19.84 $821.34M 6.25%
CSPHFCStone Pharmaceuticals $0.71 +0.00% -19.48 $1.14B 0.00%
MEOBFMesoblast Limited $1.70 +0.00% -22.15 $2.20B 0.00%
NPPNYNippon Shinyaku Co., Ltd. $6.00 +0.00% 9.11 $1.62B 1.83%

About Kuros Biosciences AG

Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fosters external partnerships, notably collaborating with Checkmate Pharmaceuticals LLC on the development of CYT003, an oncology treatment.

Kuros Biosciences AG is headquartered in CH.

Kuros Biosciences AG (CSBTF) stock trades at $25.57 with a market capitalization of $1.01B. The stock is valued at a price-to-earnings (P/E) ratio of 478.87, price-to-book of 11.93, price-to-sales of 6.21. Over the past 52 weeks the stock has ranged between $22.72 and $42.81, and currently trades 40.3% below its 52-week high.

On profitability, Kuros Biosciences AG generates a return on equity (ROE) of 2.28%, return on capital employed of 10.51%, an operating margin of 5.99%, a net profit margin of 1.26%.

Official website: kurosbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides